Skip to main content
Supportive Care and Psychosocial Issues
May 10, 2000

Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy

Abstract

PURPOSE: Depressive symptomatology is frequently associated with interleukin (IL)-2 and interferon alfa-2b (INFα-2b) therapy in cancer patients. The objective of the present study was to evaluate the depressive and anxiety symptoms induced by IL-2 and/or INFα-2b in cancer patients during the first days of cytokine immunotherapy.
PATIENTS AND METHODS: The study included 48 patients with renal cell carcinoma or melanoma. Patients were treated either with subcutaneous IL-2, alone (n = 20) or in combination with INFα-2b (n = 6); or with INFα-2b alone, administered subcutaneously at a low dose (n = 8) or intravenously at a high dose (n = 14). Depressive symptoms were evaluated using the Montgomery and Asberg Depression Rating Scale (MADRS), and anxiety symptoms were evaluated using the Covi scale. Evaluations were performed just before initiation of treatment (day 1) and on days 3 and 5 of treatment.
RESULTS: Patients treated with IL-2 alone or in association with INFα-2b had significantly higher MADRS scores after 5 days of cytokine therapy, and patients who received both cytokines had increased scores on day 3. In contrast, patients treated with INFα-2b alone did not have varying MADRS scores during the course of treatment. Cytokine therapy had no effect on anxiety, except in patients treated with IL-2 in combination with INFα-2b. In these patients, the enhancement in anxiety scores that was observed on day 5 was mainly attributable to increased somatic complaints.
CONCLUSION: IL-2 and INFα-2b have differential effects on mood, and IL-2 therapy induces depressive symptoms early in treatment.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Journal of Clinical Oncology
Pages: 2143 - 2151
PubMed: 10811680

History

Published in print: May 10, 2000
Published online: September 21, 2016

Permissions

Request permissions for this article.

Authors

Affiliations

Lucile Capuron
From the Institut National de la Santé et de la Recherche Médicale U 394Neurobiologie Intégrative, Institut François Magendie, and Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.
Alain Ravaud
From the Institut National de la Santé et de la Recherche Médicale U 394Neurobiologie Intégrative, Institut François Magendie, and Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.
Robert Dantzer
From the Institut National de la Santé et de la Recherche Médicale U 394Neurobiologie Intégrative, Institut François Magendie, and Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Notes

Address reprint requests to Lucile Capuron, PhD, Institut National de la Santé et de la Recherche Médicale U 394, Neurobiologie Intégrative, Institut François Magendie, Rue Camille Saint-Saëns, 33077 Bordeaux Cedex, France; email lucile.capuron@vignemale .bordeaux.inserm.fr.

Metrics & Citations

Metrics

Altmetric

Citations

Article Citation

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Lucile Capuron, Alain Ravaud, Robert Dantzer
Journal of Clinical Oncology 2000 18:10, 2143-2151

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

Purchase this article to get full access to it.

Purchase this Article

Subscribe

Subscribe to this Journal
Renew Your Subscription
Become a Member

View options

View Full Text HTML

View Full Text HTML

PDF

View PDF

Media

Figures

Other

Tables

Share

Share

Share article link

Share